

SUPPLEMENTARY CORRIGENDA TO VOLUMES 1–65

Volume 62

p. 218, footnote, *replace* (103.5 kPa) *by* (101.3 kPa)

Volume 64

p. 52, 3rd paragraph, *replace* in section 3.2 *by* in section 2.4(c)

p. 57, last paragraph, 2nd line, *replace* in section 1.2 and 3.2 *by* in section 1.2 and 2.4(c)

p. 86, last line, *replace* (1995) *by* (1995a)

p. 100, Figure 15, title, *replace* HP-16 *by* HPV-16

p. 142:

2.4.1 Cervical cancer, 1st paragraph, two last lines, *replace* Bosch *et al.*, 1992 *by* Bosch & Muñoz, 1989 *and add* Muñoz *et al.*, 1994.

(a) title, *replace* CIN III *by* CIN I–III

p. 173, 2nd paragraph, last line, *replace* Muñoz *et al.*, 1994 *by* Muñoz *et al.*, 1992

p. 174, before last two lines, *add* heading (c) *HPV antibodies in CIN and invasive carcinoma*

p. 195, 2nd paragraph, last line, *replace* Muñoz *et al.*, 1994 *by* Muñoz *et al.*, 1995b; 6th paragraph, last line, *add* Muñoz *et al.*, 1995b

p. 342, Muñoz *et al.*, 1995 *is* 1995a. Also *add* Muñoz, N., Kato, I., Bosch, F.X., De Sanjosé, S., Sundquist, V.-A., Izarzugaza, I., Gonzalez, L.C., Tafur, L., Gili, M., Viladiu, P., Navarro, C., Moreo, P., Guerrero, E., Shah, K.V. & Wahren, B. (1995b) Cervical cancer and herpes simplex virus type 2: case-control studies in Spain and Colombia, with special reference to immunoglobulin-G sub-classes. *Int. J. Cancer*, **60**, 438–442

Volume 65

p. 348 *should be* p. 351

p. 351 *should be* p. 348